Eone Diagnomics Genome Center Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 2/6
Eone Diagnomics Genome Center has a total shareholder equity of ₩72.4B and total debt of ₩55.6B, which brings its debt-to-equity ratio to 76.8%. Its total assets and total liabilities are ₩164.1B and ₩91.7B respectively.
Anahtar bilgiler
76.8%
Borç/özkaynak oranı
₩55.59b
Borç
| Faiz karşılama oranı | n/a |
| Nakit | ₩10.23b |
| Eşitlik | ₩72.38b |
| Toplam yükümlülükler | ₩91.72b |
| Toplam varlıklar | ₩164.09b |
Son finansal sağlık güncellemeleri
Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?
Apr 06
Eone Diagnomics Genome Center (KOSDAQ:245620) Is Carrying A Fair Bit Of Debt
Dec 16Recent updates
There's No Escaping Eone Diagnomics Genome Center Co., Ltd.'s (KOSDAQ:245620) Muted Revenues Despite A 43% Share Price Rise
Feb 29Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?
Apr 06If You Had Bought Eone Diagnomics Genome Center (KOSDAQ:245620) Shares A Year Ago You'd Have Earned 54% Returns
Feb 24Do Insiders Own Lots Of Shares In Eone Diagnomics Genome Center Co., Ltd. (KOSDAQ:245620)?
Jan 20Eone Diagnomics Genome Center (KOSDAQ:245620) Is Carrying A Fair Bit Of Debt
Dec 16Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: A245620's short term assets (₩38.3B) do not cover its short term liabilities (₩45.0B).
Uzun Vadeli Yükümlülükler: A245620's short term assets (₩38.3B) do not cover its long term liabilities (₩46.7B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: A245620's net debt to equity ratio (62.7%) is considered high.
Borcun Azaltılması: A245620's debt to equity ratio has increased from 10.8% to 76.8% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: A245620 has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: A245620 is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.